

19. Nistri S, Olivotto I, Maron MS, et al. β Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. *Am J Cardiol.* 2012 Sep;110(5):715-719.
20. Anderson DM, Raff GL, Ports TA, et al. Hypertrophic obstructive cardiomyopathy. Effects of acute and chronic verapamil treatment on left ventricular systolic and diastolic function. *Br Heart J.* 1984;51(5):523-529.
21. Bonow RO, Dilsizian V, Rosing DR, et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. *Circulation.* 1985;72(4):853-864.
22. Kimmelstiel C, Zisa DC, Kuttub JS, et al. Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes. *Circ Cardiovasc Interv.* 2019;12(7):e007673.
23. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. *Eur Heart J.* 2023;44(37):3503-3626.

Zkrácenou informací o přípravku naleznete zde:
https://www.bms.com/assets/bms/cz/en/documents/CAMZYOS_ZIP.pdf

3500-CZ-2400021